Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann’s thrombasthenia registry
dc.contributor.author | Recht, Michael | |
dc.contributor.author | Rajpurkar, Madhvi | |
dc.contributor.author | Chitlur, Meera | |
dc.contributor.author | d’Oiron, Roseline | |
dc.contributor.author | Zotz, Rainer | |
dc.contributor.author | Di Minno, Giovanni | |
dc.contributor.author | Cooper, David L. | |
dc.contributor.author | Poon, Man‐chiu | |
dc.date.accessioned | 2017-06-16T20:10:14Z | |
dc.date.available | 2018-08-28T15:28:59Z | en |
dc.date.issued | 2017-07 | |
dc.identifier.citation | Recht, Michael; Rajpurkar, Madhvi; Chitlur, Meera; d’Oiron, Roseline; Zotz, Rainer; Di Minno, Giovanni; Cooper, David L.; Poon, Man‐chiu (2017). "Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann’s thrombasthenia registry." American Journal of Hematology 92(7): 646-652. | |
dc.identifier.issn | 0361-8609 | |
dc.identifier.issn | 1096-8652 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/137322 | |
dc.description.abstract | Glanzmann’s thrombasthenia (GT) is a rare congenital bleeding disorder associated with decreased platelet aggregation due to qualitative/quantitative deficiencies of the fibrinogen receptor. Severe bleeding episodes and perioperative bleeding are typically managed with platelet transfusions, although patients can develop antiâ platelet antibodies or experience clinical refractoriness. The GT Registry (GTR) was established to collect efficacy/safety data on hemostatic treatments for GT, including recombinant factor VIIa (rFVIIa). At the request of the United States Food and Drug Administration, three hematology experts evaluated platelet refractoriness, antibody status, and rFVIIa efficacy data on a caseâ byâ case basis to support a potential indication for rFVIIa in GT. Adjudication included 195 patients with 810 events (619 severe bleeding episodes, 192 surgeries), and a consensus algorithm was developed to describe adjudicators’ coding of refractoriness and antibody status based on treatment patterns over time. Most rFVIIaâ treated events were in patients without refractoriness or antibodies. Adjudicators rated most rFVIIaâ treated bleeding episodes as successful (251/266, 94.4%; rFVIIa only, 101/109, 92.7%; rFVIIaâ ±â plateletsâ ±â other agents, 150/157, 95.5%); efficacy was consistent in patients with platelet refractorinessâ ±â antibodies (75/79, 94.9%), antibodies only (10/10, 100.0%), and neither/unknown (166/177, 93.8%). Adjudicators also rated most rFVIIaâ treated surgeries as successful (159/160, 99.4%; rFVIIa only, 65/66, 98.5%; rFVIIaâ ±â plateletsâ ±â other agents, 94/94, 100.0%); efficacy was consistent in patients with platelet refractorinessâ ±â antibodies (69/70, 98.6%), antibodies only (24/24, 100.0%), and neither/unknown (66/66, 100.0%). Unblinding the adjudicators to investigator efficacy ratings changed few assessments. Doses of rFVIIa were narrowly distributed, regardless of other hemostatic agents used. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.title | Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann’s thrombasthenia registry | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.subject.hlbtoplevel | Science | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/137322/1/ajh24741.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/137322/2/ajh24741_am.pdf | |
dc.identifier.doi | 10.1002/ajh.24741 | |
dc.identifier.source | American Journal of Hematology | |
dc.identifier.citedreference | Di Minno G, Coppola A, Di Minno MN, et al. Glanzmann’s thrombasthenia (defective platelet integrin alphaIIbâ beta3): proposals for management between evidence and open issues. Thromb Haemost. 2009; 102: 1157 â 1164. | |
dc.identifier.citedreference | Bellucci S, Caen J. Molecular basis of Glanzmann’s Thrombasthenia and current strategies in treatment. Blood Rev. 2002; 16: 193 â 202. | |
dc.identifier.citedreference | NovoSeven RT Coagulation Factor VIIa (Recombinant) [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2014. | |
dc.identifier.citedreference | Poon MC, d’Oiron R, Zotz RB, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica. 2015; 100: 1038 â 1044. | |
dc.identifier.citedreference | Spiess BD. Platelet transfusions: the science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol. 2010; 24: 65 â 83. | |
dc.identifier.citedreference | Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Rev Hematol. 2012; 5: 487 â 503. | |
dc.identifier.citedreference | George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood. 1990; 75: 1383 â 1395. | |
dc.identifier.citedreference | Chitlur M, Rajpurkar M, Recht M, et al. Independent adjudicator assessment of efficacy of recombinant factor VIIa in bleeding/surgery in the Glanzmann’s thrombasthenia registry (GTR). Haemophilia. 2015; 21: e261. | |
dc.identifier.citedreference | Di Minno G, Zotz RB, d’Oiron R, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of nonâ surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015; 100: 1031 â 1037. | |
dc.identifier.citedreference | NovoSeven [Summary of Product Characteristics]. Novo Nordisk A/S, Bagsvaerd, Denmark. July 2013. | |
dc.identifier.citedreference | Poon MC. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia. Vasc Health Risk Manag. 2007; 3: 655 â 664. | |
dc.identifier.citedreference | Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factorâ independent thrombin generation. Blood. 2003; 101: 1864 â 1870. | |
dc.identifier.citedreference | Lisman T, Adelmeijer J, Heijnen HF, et al. Recombinant factor VIIa restores aggregation of alphaIIbbeta3â deficient platelets via tissue factorâ independent fibrin generation. Blood. 2004; 103: 1720 â 1727. | |
dc.identifier.citedreference | Rajpurkar M, Chitlur M, Recht M, et al. Use of recombinant activated factor VII in patients with Glanzmann’s thrombasthenia: a review of the literature. Haemophilia. 2014; 20: 464 â 471. | |
dc.identifier.citedreference | Poon MC, d’Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost. 2004; 2: 1096 â 1103. | |
dc.identifier.citedreference | Lak M, Scharling B, Blemings A, et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia. 2008; 14: 103 â 110. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.